Recommendation 28: We recommend an ACE inhibitor, or ARB in those with ACEi intolerance, in patients with acute MI with HF or an EF < 40% post-MI to be used as soon as safely possible post- MI and be continued indefinitely (Strong Recommendation, High Quality Evidence).